immateria medica

Polquff Corporation has steadfastly advocated Maltriximub XD (cerephasmine HCL) for the treatment of polyacrylosis in Cherethryggs, but Drs. Eirtheyck Sagdwa and Karmayall Gleiss say that the procedures under which Maltriximub XD was tested employed an accidental synergy between cerephasmine and one of the excipients, a low molecular weight peptide from the Yissurogue tree generally thought to be decomposed to component peptide residues in the stomachs of the Cherethryggs, which reacts with cerephasmine to form yissurogin cerephasmide, which is cleaved into oxorin (glucuronidated in the Cherethrygg liver and completely eradicated from the system) and yissurophasmine, which is a stronger agonist of the D-32 receptor than cerephasmine. In fact, traditional Cherethrygg remedies for polyacrylosis usually employ Yissurogue bark and cerephal snail slime, but they only get cerephamine from the snail slime, and thus the yissurogin cerephamine which forms is only a weak agonist for the D-32 receptor, but strong enough to have measurable therapeutic value. Regrettably for Polquff, and victoriously for the Cherethryggs, cerephasmine is not under patent. However, as strong an agonist for the D-32 receptor as yissurophasmine is, any reasonable polyacrylosis therapy should include all three corners of Van Wylthoff's triangle: the D-32 receptor (cerephasmine, yissurophasmine, yissurophamine), blocking the kliadotropin pathway by inhibiting synthesis of galioganol (which is usually accomplished by low doses of tereschyllin or pereschyllin), and preventing low width S receptor decoupling which can either be done by dietary changes (restricting the consumption of the "scar" and "burn" foods and encouraging the production of the "ice" and "steam" foods in the traditional Cherethrygg dietary classification) or by monthly injections of taramifub or gloxoflast.